提示: 手机请竖屏浏览!

冰岛人群对SARS-CoV-2的体液免疫应答
Humoral Immune Response to SARS-CoV-2 in Iceland


Daniel F. Gudbjartsson ... 呼吸系统疾病 • 2020.10.29
相关阅读
• 抗体监测的强大实力

3万人研究:SARS-CoV-2致死风险0.3%,抗体水平4个月内持平

 

张林琦

清华大学医学院;清华大学万科公共卫生与健康学院

 

抗体是人体免疫系统关键的组成部分,在抗感染、炎症和肿瘤反应等方面起着极其重要的作用。当人体被病毒感染或疫苗接种后,诱导产生抗体反应的水平和持续时间,存在着很大差别。一般来讲,抗体反应越强,持续的时间越长,对机体的保护能力越高越持久。SARS-CoV-2感染后,抗体在人体内反应的动态变化是领域研究的重点。

查看更多

摘要


背景

关于人体感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)后体液免疫应答的特点和持久性,目前仍知之甚少。

 

方法

我们应用6种检测法(包括两种全类别免疫球蛋白[pan-Ig]检测法)测定了冰岛30,576人血清样本内的抗体;血清反应阳性的判定指标是两种pan-Ig检测法的结果均呈阳性。我们检测了在定量聚合酶链反应(qPCR)确诊感染后4个月内采集的1,237人的2,102份样本,以及曾暴露于SARS-CoV-2的4,222名被隔离人员和23,452名未发生已知暴露人员的抗体。

 

结果

在SARS-CoV-2感染后已康复的1,797人中,1,215名被检测者中有1,107名(91.1%)呈血清反应阳性;两种pan-Ig检测法测出的抗病毒抗体滴度在qPCR确诊感染后的2个月期间升高,并在之后的研究期间维持稳定。在被隔离人员中,2.3%呈血清反应阳性;在未发生已知暴露的人员中,0.3%呈阳性。我们估计有0.9%的冰岛人曾感染SARS-CoV-2,其中0.3%导致了死亡。我们还估计在冰岛的所有SARS-CoV-2感染者中,有56%曾通过qPCR确诊,有14%发生于未接受qPCR检测的被隔离人员(或者qPCR检测后结果并非阳性者),30%发生于未被隔离且未接受qPCR检测的人员。

 

结论

我们的研究结果表明,针对SARS-CoV-2的抗病毒抗体在确诊感染后4个月内并未下降。我们估计因感染SARS-CoV-2而死亡的风险为0.3%,冰岛感染者中有44%未经过qPCR确诊。





作者信息

Daniel F. Gudbjartsson, Ph.D., Gudmundur L. Norddahl, Ph.D., Pall Melsted, Ph.D., Kristbjorg Gunnarsdottir, M.Sc., Hilma Holm, M.D., Elias Eythorsson, M.D., Ph.D., Asgeir O. Arnthorsson, M.Sc., Dadi Helgason, M.D., Ph.D., Kristbjorg Bjarnadottir, Ph.D., Ragnar F. Ingvarsson, M.D., Brynja Thorsteinsdottir, B.Sc., Steinunn Kristjansdottir, B.Sc., Kolbrun Birgisdottir, B.Sc., Anna M. Kristinsdottir, M.Sc., Martin I. Sigurdsson, M.D., Ph.D., Gudny A. Arnadottir, M.Sc., Erna V. Ivarsdottir, M.Sc., Margret Andresdottir, M.Sc., Frosti Jonsson, M.Sc., Arna B. Agustsdottir, M.Sc., Jonas Berglund, Ph.D., Berglind Eiriksdottir, Run Fridriksdottir, M.Sc., Elisabet E. Gardarsdottir, Magnus Gottfredsson, M.D., Ph.D., Olafia S. Gretarsdottir, B.Sc., Steinunn Gudmundsdottir, M.Sc., Kjartan R. Gudmundsson, B.Sc., Thora R. Gunnarsdottir, B.Sc., Arnaldur Gylfason, M.Sc., Agnar Helgason, Ph.D., Brynjar O. Jensson, M.Sc., Aslaug Jonasdottir, M.Sc., Hakon Jonsson, Ph.D., Thordur Kristjansson, M.D., Ph.D., Karl G. Kristinsson, M.D., Ph.D., Droplaug N. Magnusdottir, M.Sc., Olafur T. Magnusson, Ph.D., Lovisa B. Olafsdottir, M.D., Solvi Rognvaldsson, B.Sc., Louise le Roux, M.Sc., Gudrun Sigmundsdottir, M.D., Asgeir Sigurdsson, B.Sc., Gardar Sveinbjornsson, M.Sc., Kristin E. Sveinsdottir, B.Sc., Maney Sveinsdottir, B.Sc., Emil A. Thorarensen, B.Sc., Bjarni Thorbjornsson, B.Sc., Marianna Thordardottir, Ph.D., Jona Saemundsdottir, B.Sc., S. Hjortur Kristjansson, M.D., Kamilla S. Josefsdottir, M.D., Gisli Masson, Ph.D., Gudmundur Georgsson, B.Sc., Mar Kristjansson, M.D., Alma Moller, M.D., Ph.D., Runolfur Palsson, M.D., Thorolfur Gudnason, M.D., Unnur Thorsteinsdottir, Ph.D., Ingileif Jonsdottir, Ph.D., Patrick Sulem, M.D., and Kari Stefansson, M.D., Ph.D.
From deCODE Genetics/Amgen (D.F.G., G.L.N., P.M., K.G., H.H., A.O.A., K. Bjarnadottir, B. Thorsteinsdottir, S.K., K. Birgisdottir, A.M.K., G.A.A., E.V.I., M.A., F.J., A.B.A., J.B., B.E., R.F., E.E.G., S.G., K.R.G., A.G., A.H., B.O.J., A.J., H.J., T.K., D.N.M., O.T.M., S.R., L.R., A.S., G. Sveinbjornsson, K.E.S., E.A.T., B. Thorbjornsson, J.S., G.M., G.G., U.T., I.J., P.S., K.S.), the School of Engineering and Natural Sciences (D.F.G., P.M.), the Department of Anthropology (A.H.), the BioMedical Center (K.G.K.), and the Faculty of Medicine, School of Health Sciences (M.I.S., M.G., K.G.K., R.P., U.T., I.J., K.S.), University of Iceland, Internal Medicine and Rehabilitation Services (E.E., D.H., R.F.I., M.G., L.B.O., M.K., R.P.), the Division of Anesthesia and Intensive Care Medicine (M.I.S.), and the Department of Clinical Microbiology (O.S.G., T.R.G., K.G.K., M.S.), Landspitali–the National University Hospital, and the Directorate of Health (G. Sigmundsdottir, M.T., K.S.J., A.M., T.G.), Reykjavik, and the Health Care Institution of South Iceland, Selfoss (S.H.K.) — all in Iceland. Address reprint requests to Dr. Stefansson at deCODE Genetics–Amgen, Sturlugata 8, Reykjavik 102, Iceland, or at kstefans@decode.is.

 

参考文献

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

2. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity 2020;52:910-941.

3. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020 March 28 (Epub ahead of print).

4. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396:535-544.

5. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020;26:1200-1204.

6. Streeck H, Schulte B, Kuemmerer B, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event (https://www.medrxiv.org/content/10.1101/2020.05.04.20090076v2. opens in new tab). preprint.

7. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Euro Surveill 2020;25(12).

8. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20:669-677.

9. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 2020;11:3436-3436.

10. Meyer B, Torriani G, Yerly S, et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect 2020 June 27 (Epub ahead of print).

11. Beavis KG, Matushek SM, Abeleda APF, et al. Evaluation of the EUROIMMUN anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies. J Clin Virol 2020;129:104468-104468.

12. Jääskeläinen AJ, Kuivanen S, Kekäläinen E, et al. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol 2020;129:104512-104512.

13. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med 2020;382:2302-2315.

14. Adams ER, Ainsworth M, Anand R, et al. Antibody testing for COVID-19: a report from the National COVID Scientific Advisory Panel (https://www.medrxiv.org/content/10.1101/2020.04.15.20066407v3. opens in new tab). preprint.

15. Adams SH, Park MJ, Schaub JP, Brindis CD, Irwin CE Jr. Medical vulnerability of young adults to severe COVID-19 illness — data from the National Health Interview Survey. J Adolesc Health 2020 July 9 (Epub ahead of print).

16. Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020;55:2000688-2000688.

17. Dörner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity 2007;27:384-392.

18. Deng W, Bao L, Liu J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 2020;369:818-823.

服务条款 | 隐私政策 | 联系我们